Pfizer eyes PhIII with impressive data for breast-cancer fighter
The U.S. drug giant's interim data bolster its decision to keep the program amid a spate of deals to license out other clinical-stage oncology assets in recent years of R&D cost cutting.
Targacept taps Stephen A. Hill to serve as president and CEO
Targacept ($TRGT) tapped Stephen A. Hill to serve as president and CEO, effective Dec. 1. Hill will also join the company's board of directors. The doctor brings more than 20 years of industry experience to the role, having served previously as president and CEO of both Solvay Pharmaceuticals and ArQule ($ARQL). At Solvay, he led an organization of more than 1,200 employees until Abbott Laboratories ($ABT) acquired the company in 2010. And at ArQule, he led a successful transition from a fee-for-service discovery chemistry model to an enterprise with a proprietary clinical-stage pipeline. "I believe there is tremendous potential at Targacept to build upon a strong scientific and financial foundation and a promising clinical portfolio to deliver new treatment options to patients in need," Hill said in a statement. Release
Biotech
> Emergent BioSolutions ($EBS) named Robert G. Kramer CFO. Kramer currently works as executive vice president of the corporate services division. He will continue in that position in addition to his new role. Release
> Echo Therapeutics ($ECTE) hired Daniel Sunday as vice president of manufacturing and global supply chain. Sunday joins Echo from Animas, a Johnson & Johnson ($JNJ) company. Release
> Aurobindo Pharma named Arvind Vasudeva as CEO (Formulations). Prior to joining the company, Vasudeva served as chief operating officer at Glenmark Pharmaceuticals. News
> Microbix Biosystems called upon Vaughn Embro-Pantalony to serve as president and CEO. Embro-Pantalony has served as a senior executive at Novopharm and Bayer Healthcare, among others. Release
> Kala Pharmaceuticals added Bernard Gilly to its board of directors. Gilly most recently served as founding chairman and CEO of Fovea Pharmaceuticals. Release
> Regulus Therapeutics ($RGLS) named Victor Knopov vice president of pharmaceutical development. Knopov signs on with the company from Nitto Denko Technology. Release
> ImmunoGen ($IMGN) announced Charles Morris will serve as executive vice president and chief development officer. Morris was the executive vice president and chief medical officer at Allos Therapeutics. Release
TOP HEADLINES
Featured Story
10 major pharmas unite in 'pioneering' stem cell effort
Roche has taken a lead role in rallying 9 other large drugmakers and additional stakeholders to build a major collection of 1,500 induced pluripotent stem cell lines for use in early testing of drugs against a range of neurological ailments as well as diabetes.
Teva CEO Levin faces pressure from long-suffering investors
Teva investors are waiting for a word from CEO Jeremy Levin. But not just any word.
Why George Scangos deserves credit for Biogen's hot streak
Industry watchers argue that Scangos deserves kudos for the success of the biotech powerhouse since his tenure began, Forbes editor Matthew Herper writes in a feature on the chief executive's impact.
FDA matches most new drug approvals in years in 2012, but is it enough?
The FDA has highlighted the agency's 35 new drug approvals in fiscal year 2012 and its track record for beating regulators in other countries as the first to green-light therapies three-quarters of the time.
Eli Lilly touts antibody that reverses symptom of Alzheimer's
Eli Lilly's dogged pursuit of a new therapy for Alzheimer's has led to the discovery of an experimental antibody that wipes out some of the sturdier brain plaques associated with progression of the memory-stealing disease. With impressive mouse data in hand, Reuters reported, the drug giant plans to jump into human development within a year.
Against tough odds, Lundbeck touts high-stakes R&D end game
With revenue numbers sliding now that Lexapro is getting battered by generic competition, Lundbeck has been refining its late-stage R&D game, and top execs want the world to know that it has a comeback strategy.
From Our Sister Sites
The FDA gave its blessing to 35 new drugs during fiscal 2012, a number that matches last year's total--and that put the agency ahead of other regulators in approving new therapies first.
Functional Neuromodulation's deep-brain stimulation device has been implanted into its first U.S. Alzheimer's patient--the first surgery of its kind here.
POPULAR COMMENT THREADS